Drew Moghanaki, Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at David Geffen School of Medicine at UCLA, shared a post by UCLA Thoracic Surgery on X, adding:
“Lots of hope for SGLT2 inhibitors to treat early stage lung cancers. Especially when they’re still just a GGO.”
Quoting UCLA Thoracic Surgery:
“We are delighted to share that Jane Yanagawa in collaboration with Claudio Scafoglio received a $1.2M award from the UC Tobacco-Related Disease Research Program (UC TRDRP) to fund their ‘Pilot Trial of SGLT2 Inhibitor Dapagliflozin for Stage IA Lung Adenocarcinoma’.”
